Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network.
Vitale A, Leone F, Caggiano V, Hinojosa-Azaola A, Martín-Nares E, Guaracha-Basañez GA, Torres-Ruiz J, Ayumi Kawakami-Campos P, Hissaria P, Callisto A, Beecher M, Dagna L, Tomelleri A, Campochiaro C, Frassi M, Crisafulli F, Franceschini F, Hernández-Rodríguez J, Gómez-Caverzaschi V, Araújo O, Sfriso P, Bindoli S, Baggio C, Sbalchiero J, Sota J, Tufan A, Vasi I, Piga M, Cauli A, D'Agostino MA, De Paulis A, Mormile I, Mayrink Giardini HA, Cordeiro RA, Gavioli F, Lopalco G, Iannone F, Montecucco C, Monti S, Ruiz-Irastorza G, Soto-Peleteiro A, Triggianese P, Gurnari C, Viapiana O, Bixio R, Vitetta R, Conticini E, La Torre F, Ragab G, Batu ED, González-García A, Peña-Rodríguez M, Bocchia M, Wiesik-Szewczyk E, Jahnz-Rózyk K, de-la-Torre A, Balistreri A, Frediani B, Fabiani C, Cantarini L.
Vitale A, et al. Among authors: conticini e.
Front Pharmacol. 2025 Mar 7;16:1539756. doi: 10.3389/fphar.2025.1539756. eCollection 2025.
Front Pharmacol. 2025.
PMID: 40124776
Free PMC article.